

ERAPharm2007

Final programme

Wednesday 19th September

- 0920 – 0930 Welcome
Professor Mike Roberts, Central Science Laboratory
- 0930 – 0945 The ERAPHARM Project
T Knacker, ECT
- 0945 – 1020 **Plenary ‘The better analytical methods the bigger environmental problems: a fruitful relationship?’**
Professor Chris Metcalfe, Trent University, Canada
- 1020 – 1050 Coffee break/Exhibition/Posters**
- Session 1: Inputs, Analysis and Occurrence*
Chairs T Ternes and A Alder
- 1050 – 1110 The emission of pharmaceuticals from hospitals
JGM Derksen, Grontmij/Aquasense, The Netherlands
- 1110 – 1130 Drug production facilities – an overlooked discharge source of pharmaceuticals to the environment
Joakim Larsson, Goteborg University, Sweden
- 1130 – 1150 Assessment of antineoplastic drugs in hospital and urban wastewater effluents
JU Mullot, Universite Paris Sud 11, France
- 1150 – 1210 Evaluating on-line SPE-LC-IT-MS for the analysis of several classes of antibiotics in WwTP effluents
Chiron, University of Provence, France
- 1210 – 1230 Analysis of PPCPs in the Welsh aqueous environment by UPLC-MS/MS
B Kasprzyk-Hordern, University of Glamorgan, Wales
- 1230 – 1400 Lunch/Exhibition/Posters**
- 1400 – 1435 **Plenary ‘Regulatory requirements and status of environmental science: do they match?’**
Dr Kornelia Grein, EMEA, London
- Session 2: Fate and behaviour of human and veterinary medicines I*
Chairs K Fenner and B Halling Sorensen
- 1435 – 1455 VMPs in manures and manured soils: the technical protocol for laboratory tests
R Kreuzig, TU Braunschweig, Germany
- 1455 – 1515 Field evaluation of veterinary pharmaceuticals in a poultry litter windrow and possible leaching
V Furtula, Environment Canada, Canada

- 1515 – 1535 Tightlyen the concept of OECD106 and 307 to assess the fate of veterinary medicines
K Krogh, Copenhagen University, Denmark
- 1535 – 1605 Coffee break/Exhibition/Posters**
- 1605 - 1625 Are the OECD106 and 308 tests appropriate for pharmaceuticals?
M Schlusener, Federal Institute of Hydrology, Germany
- 1625 - 1645 Human medicines ERA: Phase II Tier A fate screening methods
JF Ericson, Pfizer, USA
- 1645 – 1705 Selected PPCPs in surface runoff from agricultural land receiving sewage sludge
E Topp, Agriculture and Agri-Food Canada, Canada
- 1705 – 1725 Fate of human pharmaceuticals in the soil environment
S Monteiro, University of York/CSL, UK
- 1730 Buses depart for conference hotels
- 1930 Conference Reception at The Castle Museum, York**

Thursday 20th September

- 0830 Buses depart conference hotels
- 0915-0950 **Plenary 'The development process of a human pharmaceutical: Which role plays the environmental risk assessment?'**
Dr Reinhard Lange, Schering, Germany
- Session 3: Fate and behaviour of human and veterinary medicines II*
Chairs A Boxall and C Metcalfe
- 0950 – 1010 Mechanism of Interactions of fluoroquinolone antibiotics with metals and humic substances
L Aristilde, University of California at Berkeley, USA
- 1010 - 1030 Fate of β blockers in wastewater treatment plants and in surface water
AC Alder, EAWAG, Switzerland
- 1030 - 1050 Transport of sulfadiazine in soil columns – experiments and model simulations
A Wehrhan, Forschungszentrum Julich, Germany
- 1050 – 1120 Coffee break/Exhibition/Posters**
- 1120 – 1140 Biodegradation pathway prediction using metabolic logics and thermodynamic efficiency analysis
K Fenner, EAWAG/ETH/University of Minnesota, Switzerland
- 1140 – 1200 Evaluating scenarios to assess the exposure of surface waters to veterinary medicines in Europe
M Schneider, EAWAG, Switzerland
- 1200 – 1220 Physically based solute transport models as tools in environmental risk assessments for pharmaceuticals

M Larsbo, Swedish University of Agricultural Sciences, Sweden

1220 – 1240 Estimating concentrations of pharmaceuticals in drinking water – a United Kingdom example
CD Watts, Watts and Crane Associates, UK

1240 – 1355 Lunch/Exhibition/Posters/CSL Tour

1355 – 1430 **Plenary ‘From mammalian to ecotoxicological studies: is the jump too big?’**
Professor John Sumpter, Brunel University, London

Session 4: Effects on terrestrial systems
Chairs E Topp and J Parrott

1430 – 1450 Influence of antibiotics in combination with manure on microbial N-transformation in soils
A Kotzerke, Berlin University of Technology, Germany

1450 – 1510 Effects of antibiotics on soil bacterial communities
H Schmitt, Utrecht University, The Netherlands

1510 – 1530 Effects of ivermectin on dung and soil organisms and on dung degradation under field conditions
J Rombke, ECT Oekotoxikologie GmbH, Germany

1530 – 1550 Higher tier testing of pharmaceuticals: toxicity of anthelmintics in two-species and multi-species test systems
J Jensen, NERI, Denmark

1550 – 1620 Coffee break/Exhibition/Posters

Session 5: Effects on aquatic systems 1
Chairs H Schmitt and T Hutchinson

1620 - 1640 Effects of pharmaceuticals on aquatic invertebrates in standard and non-standard tests
J Garric, Cemagref, France

1640 – 1700 Mixture toxicity of fluoxetine and its human metabolites towards algae
B Escher, EAWAG, Switzerland

1700 – 1720 An aquatic predicted no-effect concentration for ethinyl estradiol
DJ Caldwell, Johnson and Johnson, USA

1730 Buses depart for conference hotels

1930 Conference Banquet at the National Railway Museum, York

Friday 21st September

0840 Buses depart conference hotels

0925-1000 **Plenary ‘Pharmaceuticals in the environment: a problem invented by rich societies?’**
Professor Peter Calow, University Rothskilde, Denmark

Session 6: Effects on aquatic systems II
Chairs J Garric and JO Straub

1000 - 1020 Exposure of the fathead minnow (*Pimephales promelas*) to atenolol: responses at the whole animal and molecular levels
T Hutchinson, AstraZeneca, UK

1020 - 1040 Fathead minnow lifecycle exposure to the β blocker propranolol
J Parrott, Environment Canada, Canada

1040 - 1100 Alternative endpoints for risk assessment of pharmaceuticals in the environment
BW Brooks, Baylor University, USA

1100 - 1130 Coffee break/Exhibition/Posters

Session 7: Risk assessment and risk management
Chairs J Koschorreck and T Boucard

1130 - 1150 Product Stewardship in the Pharmaceutical Industry taken seriously:
Green Pharmacy
K Kummerer

1150 - 1210 Does the use of avermectins cause an environmental risk?
L Kolar, University of Ljubljana, Slovenia

1210 - 1230 Preliminary environmental risk assessment of the parasiticide ivermectin
M Liebig, ECT Oekotoxikologie GmbH, Germany

1230 - 1330 Lunch/Exhibition/Posters

1330 - 1350 Intelligent testing strategies for the environmental exposure and persistency assessments of human medicines
J Snape, AstraZeneca

1350 - 1410 ERA Testing Strategies and First Experience with the New EMEA Guideline
A Hartmann, Novartis Pharma AG, Switzerland

1410 - 1430 Deterministic and probabilistic environmental risk assessment for diazepam
JO Straub, Hoffmann-La Roche Ltd, Switzerland

1430 - 1450 Towards greener pharmaceuticals: preclinical environmental stewardship of pharmaceuticals
J Clark, University of York, UK

1450 - 1505 Closing remarks
A Boxall

1505 - 1530 Coffee break

1530 Buses depart for central York